



PRESS RELEASE

Crucell Clarifies CFO Comment Made at UBS Conference

Leiden, The Netherlands, September 27, 2005 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) wishes to clarify a comment made by its Chief Financial Officer Leonard Kruimer at the UBS Global Life Sciences conference in New York on Monday September 26.

During his presentation Mr Kruimer commented on Crucell's current year revenues, saying that "in the third quarter alone we (the Company) will comfortably pass the entire sales of last year". Crucell wishes to make clear that Crucell's total revenues for the first three quarters of 2005 are forecast to exceed the full-year sales of 2004.

A webcast of Mr Kruimer's UBS presentation is accessible via the Crucell website until October 29.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6[®] production technology. The company also licenses its PER.C6[®] technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.

Harry Suykerbuyk
Director Investor Relations and
Corporate Communications
Tel. +31-(0)71-524 8718
h.suykerbuyk@crucell.com

For Crucell in the US: Redington, Inc.

Thomas Redington
Tel. +1 212-926-1733
tredington@redingtoninc.com